Kinarus Therapeutics Shareholders Approve All Board Proposals at the 2023 Annual General Meeting
Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus” or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, announces that its shareholders have approved all proposals by the Board of Directors at the 2023 Annual General Meeting ("AGM"), held yesterday at the Radisson Blu Hotel Basel, Steinentorstrasse 25, 4051 Basel, Switzerland.
- Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus” or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, announces that its shareholders have approved all proposals by the Board of Directors at the 2023 Annual General Meeting ("AGM"), held yesterday at the Radisson Blu Hotel Basel, Steinentorstrasse 25, 4051 Basel, Switzerland.
- Furthermore, the shareholders granted discharge to the members of the Board of Directors and Executive Management for the financial year 2022.
- The “Invitation to the 2023 Annual General Meeting” with full proposals and explanations on the agenda items are available on Kinarus’ website at https://ir.kinarus.com/2023-agm/.
- Kinarus possesses the exclusive worldwide license to pamapimod, covering all indications, and has patented KIN001, its novel mechanism in combination with pioglitazone.